EVENTS|NEWS|CONTACT|DONATE

Gastric Cancer
Accelerate Research
Patient Resources
Nutrition
- Eating and Healing
- Gesundheit Kitchen
  - Watch Episodes
  - Printable Recipes
Ways to Give
About Us

Read Our Newsletter

Gastric Cancer
Accelerate Research
Patient Resources
Nutrition
- Eating and Healing
- Gesundheit Kitchen
  - Watch Episodes
  - Printable Recipes
Ways to Give
About Us

News in Gastric Cancer

News from around the world, curated by the Gastric Cancer Foundation.

dna research

In JAMA Oncology Publication, GeneDx Describes Lower Lifetime Risk of Gastric Cancer Conferred by CDH1

A study by GeneDx shows that the lifetime risk for gastric cancer in people with pathogenic CDH1 variants is 42% for men and 33% for women—a more precise estimate than what was available before.

CDH1, men, risk, studies, women

Share Post:

Predictors of Response to Immune Checkpoint Inhibitors in Patients With Advanced Esophagogastric Cancer

Gastric cancer risks due to CDH1 variant likely overestimated

Social Media

Newsroom

For press inquiries about the Gastric Cancer Foundation, please contact: Mediainfo@gastriccancer.org

Categories

Foundation News
Press Releases
Research News

Tags

adenocarcenoma advanced stage alcohol antibody biomarker blood chemoradiotherapy chemotherapy clinical trial clinical trials detection drugs endoscopy Epstein-Barr esophagogastric FDA gastrectomy gastric cancer registry gastroesophageal genes heartburn helicobacter pylori HER2 immunotherapy keytruda lonsurf metastatic nutrition peritoneal postoperative prevention proton pump inhibitor recovery recurrence research risk screening side-effects studies surgery survival treatment tumor virus women

Gastric Cancer Foundation

Tax ID 27-2978173

info@gastriccancer.org

PO Box 338
Millbrae, CA 94030

For Deliveries:
Gastric Cancer Foundation
501 Broadway, #338
Millbrae, CA 94030-1907

Site Map

Gastric Cancer
Accelerate Research
Patient Resources
Nutrition
- Eating and Healing
- Gesundheit Kitchen
  - Watch Episodes
  - Printable Recipes
Ways to Give
About Us

Social Feed

Gastric Cancer Foundation

17 hours ago

Adding immunotherapy to chemotherapy has been a “significant advance” in treating gastric cancer, but questions remain, says Samuel Cytryn, MD, a gastrointestinal oncologist at Memorial Sloan Kettering Cancer Center in New York.www.oncologynewscentral.com/article/most-significant-advance-in-gastric-cancer-care-leads-to-new-... ... See MoreSee Less

View on Facebook

· Share

Share on Facebook Share on Twitter Share on Linked In Share by Email

Gastric Cancer Foundation

1 week ago

In a trial, treating gastric cancer patients with chemoradiotherapy prior to surgery did not boost survival rates. ... See MoreSee Less

Survival Rates with Preoperative Chemoradiotherapy for Resectable Gastric Cancer

www.physiciansweekly.com

The following is a summary of

View on Facebook

· Share

Share on Facebook Share on Twitter Share on Linked In Share by Email

Gastric Cancer Foundation

2 weeks ago

I-Mab’s bispecific antibody targeting CLDN18.2 showed promising efficacy as a solo treatment for gastric cancer patients in an early trial.www.nasdaq.com/articles/i-mab-reports-promising-results-phase-1-study-givastomig-gastric-cancer ... See MoreSee Less

View on Facebook

· Share

Share on Facebook Share on Twitter Share on Linked In Share by Email

Gastric Cancer Foundation

2 weeks ago

For some patients with gastric cancer, the risks outweigh the benefits of checkpoint-inhibiting immunotherapy drugs, the U.S. Food and Drug Administration says. ... See MoreSee Less

FDA ODAC Finds Limited Benefit for Checkpoint Inhibitors in Low PD-L1 Gastric Cancer

www.targetedonc.com

The FDA’s Oncologic Drug Advisory Committee voted against the use of checkpoint inhibitors in first-line advanced gastric cancer with PD-L1 expression less than 1.

View on Facebook

· Share

Share on Facebook Share on Twitter Share on Linked In Share by Email

Gastric Cancer Foundation

2 weeks ago

The new gastric cancer treatment Vyloy (zolbetuximab-clzb), which targets the tumor protein claudin 18.2, “is an important step forward for patients suffering from this serious and often fatal cancer,” said Professor Florian Lordick, Director of the University Cancer Center Leipzig, which was a clinical trial site for the drug. ... See MoreSee Less

Drug Extends Survival in Gastric Cancer Clinical Trial

www.technologynetworks.com

A new study reveals that gastric cancer patients treated with zolbetuximab live longer.

View on Facebook

· Share

Share on Facebook Share on Twitter Share on Linked In Share by Email

Subscribe to Our Newsletter

We’ll deliver our monthly newsletter to your Inbox with Foundation updates, news about cutting edge research and trends in the field, and how to make a difference.

© 2024 Gastric Cancer Foundation. All Rights Reserved.

EVENTS | NEWS | CONTACT | DONATE

Please join with us to fuel the next wave of progress.

Your support today will honor the memories of those we have lost and create much-needed hope for those who are bravely facing the disease today. Contributions are tax-deductible.

Please join with us to fuel the next wave of progress. Support our 2024 Fundraising Campaign.

Your support today will honor the memories of those we have lost and create much-needed hope for those who are bravely facing the disease today. Contributions are tax-deductible.

Together, we will defeat stomach cancer.

Together, we will defeat stomach cancer.

MORE INFO DONATE

X